WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017179862) ANTIBODY HAVING IMPROVED STABILITY AND SPECIFICALLY BINDING TO HER2
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/179862    International Application No.:    PCT/KR2017/003827
Publication Date: 19.10.2017 International Filing Date: 12.04.2017
IPC:
C07K 16/32 (2006.01), A61K 39/395 (2006.01), G01N 33/574 (2006.01), A61K 39/00 (2006.01)
Applicants: ABCLON INC. [KR/KR]; Suite 1401, ACE Twin Tower 1, 285, Digital-ro Guro-gu Seoul 08381 (KR)
Inventors: LEE, Jong Seo; (KR).
KIM, Kyu Tae; (KR).
LEE, Young Ha; (KR).
HWANG, In Sik; (KR).
KO, Bong Kook; (KR)
Agent: YOON, Dae Woong; (KR)
Priority Data:
10-2016-0044747 12.04.2016 KR
Title (EN) ANTIBODY HAVING IMPROVED STABILITY AND SPECIFICALLY BINDING TO HER2
(FR) ANTICORPS À STABILITÉ AMÉLIORÉE ET SE LIANT SPÉCIFIQUEMENT À HER2
(KO) 안정성이 개선된 HER2에 특이적으로 결합하는 항체
Abstract: front page image
(EN)The present invention replaces an amino acid residue of a specific region of a parent antibody so as to improve the stability of the antibody, thereby improving druggability. A variant antibody of the present invention, compared to a parent antibody hz1E11, has significantly improved stability while having nearly the same productivity and efficacy. Therefore, the variant antibody of the present invention exhibits, in the development of HER2-specific antibodies, excellent characteristics such as reduction in production costs, inhibition of efficacy reduction and reduction of side effects.
(FR)La présente invention remplace un résidu d'acide aminé d'une région spécifique d'un anticorps parent de manière à améliorer la stabilité de l'anticorps, ce qui permet d'améliorer le potentiel médicamenteux. Un anticorps variant de la présente invention, comparé à un anticorps parent hz1E11, présente une stabilité significativement améliorée tout en ayant une productivité et une efficacité pratiquement identiques. Par conséquent, l'anticorps variant de la présente invention présente, dans le développement d'anticorps spécifiques de HER2, d'excellentes caractéristiques telles que la réduction des coûts de production, l'inhibition de la réduction d'efficacité et la diminution des effets secondaires.
(KO)본 발명은 모항체의 특정 부위 아미노산 잔기를 치환하여, 항체의 안정성을 향상시켜 의약적합성(druggability)을 개선한 발명이다. 본 발명의 변이체 항체는 모항체인 hz1E11과 비교하여, 생산성과 효능이 거의 동일하면서 안정성이 크게 향상되어 있다. 따라서, 본 발명의 변이체 항체는, HER2-특이적 항체 개발에 있어서, 생산 비용 절감, 효능 감소 억제 및 부작용 감소 등의 우수한 특성을 나타낸다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)